RT Journal Article
SR Electronic
T1 Immune and pathologic responses in patients with localized prostate cancer who received daratumumab (anti-CD38) or edicotinib (CSF-1R inhibitor)
JF Journal for ImmunoTherapy of Cancer
JO J Immunother Cancer
FD BMJ Publishing Group Ltd
SP e006262
DO 10.1136/jitc-2022-006262
VO 11
IS 3
A1 Siddiqui, Bilal A
A1 Chapin, Brian F
A1 Jindal, Sonali
A1 Duan, Fei
A1 Basu, Sreyashi
A1 Yadav, Shalini S
A1 Gu, Ai-Di
A1 Espejo, Alexsandra B
A1 Kinder, Michelle
A1 Pettaway, Curtis A
A1 Ward, John F
A1 Tidwell, Rebecca S S
A1 Troncoso, Patricia
A1 Corn, Paul G
A1 Logothetis, Christopher J
A1 Knoblauch, Roland
A1 Hutnick, Natalie
A1 Gottardis, Marco
A1 Drake, Charles G
A1 Sharma, Padmanee
A1 Subudhi, Sumit K
YR 2023
UL http://jitc.bmj.com/content/11/3/e006262.abstract
AB Markup server — Error Not Found The page you were trying to reach could not be found. Please check the address for the page you were trying to reach. If you believe you have reached this page in error, you may contact us with any questions.